Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Patients with TNBC receiving NAC-I have higher pCR rates and do not appear to have added 90-day PSCs or delays to adjuvant therapy despite trending toward more extensive surgical procedures compared to NAC alone. Larger studies are needed to further evaluate the surgical safety of immunotherapy.
Authors
- Maurice J. Berkowitz
- Nimmi S. Kapoor (ORCID: https://orcid.org/0009-0002-4572-075X)
- Jennifer L. Baker (ORCID: https://orcid.org/0000-0002-4172-3083)
- Nicholas P. McAndrew (ORCID: https://orcid.org/0000-0002-6799-5204)
- Anouchka Coste Holt (ORCID: https://orcid.org/0000-0002-0408-5502)
- Courtney Smith (ORCID: https://orcid.org/0000-0002-9262-8772)
Institutions
- University of California, Los Angeles (US)
- Holy Cross Hospital (US)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1007/s12672-024-01349-7
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Center for Advancing Translational Sciences